CESAR and Saladax Biomedical Press Release

(ChemotherapyAdvisor) – A single-arm study of patients with metastatic colorectal cancer will determine whether pharmacokinetic-guided 5-fluorouracil (5-FU) regimens can provide steady dose levels while reducing toxicities such as grade 3/4 mucositis and diarrhea, Saladax Biomedical, Inc., and the Central European Society for Anticancer Drug Research (CESAR) announced today.

The collaborative trial will determine whether 5-FU target blood levels can be maintained through six courses of treatment by optimizing the dose administered to individual patients at each infusion using the Saladax Biomedical My5-FU automated immunoassay for personalized dose adjustment, according to Saladax Biomedical, Bethlehem, PA, and CESAR, Vienna, Austria.

Continue Reading

Planned enrollment at the four study sites in Germany is 80 patients and study duration is anticipated to be one year.